NMR metabonomics of cerebrospinal fluid distinguishes between Parkinson's disease and controls. (6th May 2015)

• Record Type: Journal Article
• Authors: Öhman, Anders; Forsgren, Lars
• Is Part Of: Neuroscience letters. Volume 594(2015)
• Page Start: 36
• Page End: 39
• Publication Date: 2015-05-06
• Subjects: PD Parkinson's disease -- NMR nuclear magnetic resonance -- CSF cerebrospinal fluid -- CPMG Carr-Purcell-Meiboom-Gill -- PCA principal component analysis -- PLS partial least square -- OPLS-DA orthogonal partial least square discriminant analysis -- CV-ANOVA analysis of variance testing of cross-validated predictive residuals -- VIP variable importance in the projection; Parkinson's disease -- Cerebrospinal fluid -- NMR -- Metabonomics -- Biomarker; Neurology -- Periodicals; Neurology -- Periodicals; Research -- Periodicals; Neurologie -- Périodiques; Neuroanatomie -- Périodiques; Neuropharmacologie -- Périodiques; Neurophysiologie -- Périodiques; Neurology; Periodicals; Electronic journals; 617.48
• DOI: 10.1016/j.neulet.2015.03.051
• Languages: English
• ISSNs: 0304-3940

Abstract

Highlights: NMR metabonomics identifies 60 and quantifies 38 metabolites in CSF. Patients with Parkinson's disease (PD) are distinguished from control subjects. Uni- and multivariate statistics identify nine significantly changed metabolites. Subsets of these nine metabolites also separate the PD and control groups. NMR metabonomics may provide a supporting tool useful for diagnosis of PD. Abstract: This study assesses if nuclear magnetic resonance (NMR) metabonomics can discriminate between Parkinson's disease (PD) patients and control subjects, and consequently identify metabolic markers for the disease. One-dimensional 1 H NMR spectroscopy was used for quantitative analysis of metabolites in the cerebrospinal fluid (CSF) from 10 PD patients and 10 control individuals, together with uni- and multivariate statistical analysis to discriminate between the groups and to identify significantly altered metabolite concentrations. In total 60 metabolites were identified and of those 38 were quantified in all CSF samples. An overall lowering of metabolite content was observed in PD patients compared to control subjects (fold change of 0.85 ± 0.30). Multivariate statistics reveal significant changes (ǀw*ǀ>0.2) among nine metabolites (alanine, creatinine, dimethylamine, glucose, lactate, mannose, phenylalanine, 3-hydroxyisobutyric acid and 3-hydroxyisovaleric acid). Three of these (alanine, creatinine and mannose) are identified as significantly changed also by univariate statistics ( p < 0.00132, Bonferroni corrected). Panels with all or a selected set of these metabolites were successfully used for discriminating between the two groups. In conclusion, NMR metabonomics can readily determine metabolite concentrations in CSF, identify putative biomarkers that distinguish between the PD patients and control subjects, and thus potentially become a tool for diagnostic purposes.